Gendicine, a recombinant human p53 adenovirus, was approved for use in the treatment of head and neck cancer in 2003 and has demonstrated a high level of safety in clinical application records [32] Using recombinant adenovirus vectors to reduce scarring on the lip is promising. This evidence concerns the gene TP53 and head and neck cancer.